Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Enrolling by invitation · NCT07008469 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, Myotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic dystrophy type 1, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Enrolling by invitation | Phase 3 | 2026-08-19 | NCT07008469 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Avidity Biosciences, Inc. | 6 |
35 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.